PJ-34 is a novel and potent PARP-1 inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP-1 (IC(50) = 20 nM). PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells. PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. PJ-34 reduce cell inflammation and damage that follow PARP-1 overexpression. PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells.
PJ34 HCl is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.
PARP Inhibitors Related Products:
Veliparib hcl; Olaparib; XAV-939; Rucaparib; Talazoparib; A-966492; Niraparib; Pamiparib; WIKI4; G007-LK; AZD2461; Saroglitazar; Veliparib